Farma
Frontmasta
20.06.2019 kl 22:14
3507
Husk at medisiner med patent har en høyere pris enn uten patent..........Det forteller ikke Nordic Nanovecter
2019 fra internett
Patent expiry is an issue that all successful drug makers must face eventually, and Roche is set for a particularly hazardous year on this front. Three of the Swiss company's cancer blockbusters will be opened up to cut-price competition in the US this year, though the financial impact will not be quite as painful as it could be.
2019 fra internett
Patent expiry is an issue that all successful drug makers must face eventually, and Roche is set for a particularly hazardous year on this front. Three of the Swiss company's cancer blockbusters will be opened up to cut-price competition in the US this year, though the financial impact will not be quite as painful as it could be.
Redigert 20.06.2019 kl 22:15
Rapportér innlegg
Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.